RESUMO
The COVID-19 pandemic has affected the whole world. It applies to all age and social groups. It is no different with athletes. So far, we cannot say for sure what the long-term consequences of SARS-CoV-2 infection are. Recent evidence, however, suggests that we should be very careful when returning to sports. After self-isolation, the athlete should undergo a Preparticipation Physical Examination and then pay attention to the gradual dosing of the load to prevent complications. Lifestyle changes and care for the mental health of athletes are also necessary during the illness. In this work, we present a comprehensive methodology for returning to sports after COVID-19 for medical and coaching teams caring for athletes divided according to the course of the disease. In scientific literature, similar algorithms are called "Return to Play" or "Return to Sport". Creating an exact algorithm can make the Return to Play process more efficient and safer. However, increased attention still needs to be paid to certain organ systems and specific symptoms that could indicate long-term consequences to the new type of coronavirus.
Assuntos
COVID-19 , Infecções por Coronavirus , Infecções por Coronavirus/epidemiologia , Humanos , Pandemias , Volta ao Esporte , SARS-CoV-2RESUMO
The reduction in overall mortality, cardiovascular mortality and the occurrence of myocardial infarction in patients treated with AT1 blockers is comparable with the use of ACE inhibitors. In addition, there is a lower proportion of AT1 blockers withdrawal of treatment due to adverse reactions.Key words: ACE inhibitors - AT1 blockers - cardioprotection - hypertension - renin-angiotensin-aldosteron system.
Assuntos
Bloqueadores do Receptor Tipo 1 de Angiotensina II/uso terapêutico , Hipertensão/tratamento farmacológico , Bloqueadores do Receptor Tipo 1 de Angiotensina II/efeitos adversos , Inibidores da Enzima Conversora de Angiotensina/efeitos adversos , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Doenças Cardiovasculares/tratamento farmacológico , Doenças Cardiovasculares/mortalidade , Humanos , Infarto do Miocárdio/epidemiologia , Sistema Renina-AngiotensinaRESUMO
There is no consensus of the opinion that the value of systolic blood pressure (SBP) is the most favourable for the treatment of hypertension in patients with chronic kidney disease (CKD). The interventional study SPRINT (The Systolic Blood Pressure Intervention Trial) demonstrated the significant reduction in major cardiovascular events and overall mortality with intensive control of SBP (< 120 mm Hg) in individuals with high risk, including those with CKD and mild proteinuria. Nephrologists should take into account the results of the SPRINT study in the determination of the optimal SBP in patients with CKD, but at the same time they pay the attention to the early detection of adverse events related to treatment, including disorders of electrolyte balance, acute renal impairment, hypotension, and side effects of medications.Key words: acute kidney injury - cardiovascular events - glomerular filtration rate - chronic kidney disease - proteinuria - systolic blood pressure.